Myriad Genetics Inc.

NASDAQ: MYGN · Real-Time Price · USD
5.76
-0.13 (-2.21%)
At close: Aug 15, 2025, 2:34 PM

Myriad Genetics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
837.6M 753.2M 678.4M 690.6M
Cost of Revenue
252.2M 236.2M 202M 197.6M
Gross Profit
585.4M 517M 476.4M 493M
Operating Income
-123.5M -257.4M -123.7M -48.7M
Interest Income
1.7M 2.5M 2.6M 700K
Pretax Income
-123.5M -262.2M -140.6M -57.1M
Net Income
-127.3M -263.3M -112M -27.2M
Selling & General & Admin
560M 572.9M 514.7M 599.8M
Research & Development
113.4M 88.7M 85.4M 81.9M
Other Expenses
35.5M 112.8M 600K n/a
Operating Expenses
708.9M 774.4M 600.1M 681.7M
Interest Expense
2.8M 2.9M 3.2M 6.6M
Selling & Marketing Expenses
284.1M n/a n/a n/a
Cost & Expenses
961.1M 1.01B 802.1M 879.3M
Income Tax Expense
3.8M 1.1M -28.6M -29.9M
Shares Outstanding (Basic)
90.6M 82.8M 80.58M 77.71M
Shares Outstanding (Diluted)
90.6M 82.8M 80.6M 78M
EPS (Basic)
-1.41 -3.18 -1.39 -0.35
EPS (Diluted)
-1.41 -3.18 -1.39 -0.35
EBITDA
-59.5M -186.1M -67.8M 14.1M
EBIT
-120.7M -259.3M -123.7M -48.7M
Depreciation & Amortization
61.2M 61.9M 55.9M 62.8M